Cell cycle activation and progression in vascular proliferative disease represent potent therapeutic targets. Luteolin, which occurs as glycosylated forms in celery, green pepper, perilla leaf, and camomile tea, has demonstrated antimutagenic, antitumorigenic, antioxidant, and antiinflammatory properties. In this study, we investigated the effect of luteolin on the proliferation of primary cultured rat aortic vascular smooth muscle cells induced by 5% fetal bovine serum. Luteolin at concentrations of 5, 20, and 50 μM significantly inhibited this proliferation by 29.6, 50.8, and 83.1%, respectively. The incorporation of [ 3 H]-thymidine into DNA was also inhibited by 25.8, 57.6, and 81.0%, respectively. Flow cytometry analysis of DNA content revealed that FBS-inducible cell cycle progression was blocked by luteolin. Luteolin showed no cytotoxicity in VSMCs in this experimental condition according to WST-1 assays. Luteolin may represent a potential anti-proliferative agent for treatment of angioplasty restenosis and atherosclerosis.
Introduction
Vascular smooth muscle cells (VSMCs) in the arterial media are fully differentiated to play their physiological roles as regulators of vascular wall tension. They proliferate at low indices or persist in the G0 phase of the cell cycle [1, 5] . Proliferation of VSMCs occurs in response to arterial injury and plays a crucial role in the pathogenesis of vascular disease, such as atherosclerosis, hypertension and restenosis [8] . An alternative approach to preventing the proliferation and migration of VSMCs may be to influence the downstream intracellular signaling events responsible for transducing the signals from the various growth factor receptors.
Flavonoids are naturally occurring polyphenolic compounds presented in a variety of fruits, vegetables and seeds. Flavonoids have many biological and pharmacological activities including antioxidative, antiinflammatory and antitumor effects [4] . Luteolin ( Fig. 1) , a polyphenolic compound available in foods of plant origin, belongs to the flavone subclass of flavonoids, usually occurring as glycosylated forms in celery, green pepper, perilla leaf and camomile tea [9, 10] . It has been reported to display antimutagenic, antiplatelet aggregation and anticancer effects [2, 7] .
In the present study, we investigated the antiproliferative effects of luteolin on primary cultured VSMCs stimulated by the administration of fetal bovine serum (FBS). Our results reveal that luteolin is a potential agent for the treatment of vascular disorders like atherosclerosis.
Materials and Methods

Chemicals and reagents
Luteolin (Sigma Chemical Co., MO, USA) was dissolved in dimethyl sulfoxide (DMSO) and further diluted in Dulbecco's Modified Eagle Medium (DMEM) without FBS. The cell culture materials were obtained from Gibco-BRL (Rockville, MD, USA), and other chemical reagents were from Sigma Chemical Co.
[³H]-thymidine was purchased Amersham Pharmacia Biotech (Buckingamshire, UK). Other chemicals were of analytical grade. Male Sprague-Dawley rats (Samtako Bio Korea Co., Ltd., Osan, Korea) weighing around 280 g were fed a normal chow diet and given water ad libitum. VSMCs were isolated by enzymatic dispersion as previously described [6] according to the modified method of Chamley et al. [3] . Cells were cultured in DMEM supplemented with 10% FBS, 100 IU/ml penicillin, 100 μg/ml streptomycin, 8 mM HEPES, 2 mM L-glutamine at 37°C in a humidified atmosphere of 95% air and 5% CO2 incubator. The purity of VSMCs culture was confirmed by immunocytochemically based on α-smooth muscle actin localization. The passage of VSMCs used in this experiment was 5-9.
Cell counts
VSMCs were seeded onto 12-well culture plates at 1×10 5 cells/ml, and then cultured in DMEM containing 10% FBS at 37°C for 24 hr. Under these conditions, a cell confluence of 70% was reached. The medium was then replaced with serum-free medium containing luteolin (5, 20 or 50 μM), and cells were then stimulated with 5% FBS and trypsinized using trypsin-EDTA, and counted using a hemocytometer.
DNA synthesis by [ 3 H]-thymidine incorporation
For [ 3 H]-thymidine incorporation experiments, VSMCs were seeded onto 24-well culture plates using conditions identical to those described above, and 1 μCi/ml of [ 3 H]-thymidine was added to medium. Reactions were terminated by aspirating the medium and subjecting the cultures to sequential washes with phosphate-buffered saline (PBS) containing 10% trichloroacetic acid and ethanol/ether (1:1, v/v) on ice. The acid-insoluble [ 3 H]-thymidine was extracted into 250 μl of 0.5 M NaOH/well, and this solution was mixed with a 3 ml scintillation cocktail (Ultimagold, Packard Bioscience, CT, USA). The mixed solution was quantified using a liquid scintillation counter (LS3801, Beckman, Düsseldorf, Germany), and 50 μl of residual solution was measured using a BCA Protein Assay Reagent Kit (Pierce Biotechnology, Rockford, IL, USA).
Cell viability assay For WST-1 assay (Premix WST-1, Takara, Japan), VSMCs were seeded in 96-well plates at 8×10 3 cells/well and pre-cultured in serum-free medium in the presence or absence of luteolin compounds for 24 hr. WST-1 reagent was added at 20 hr and further incubated for 4 hr. Then the absorbance was determined in an ELISA at a wavelength of 450 nm.
Cell cycle progression analysis
To estimate the proportion of cells in the various phases of the cell cycle, cellular DNA contents were measured by flow cytometry (FACS). Cells were harvested, fixed in 70% ethanol, and stored at -20°C. Cells were then washed twice with ice-cold PBS and incubated with RNase and propidium iodide (PI), a DNA-intercalating dye. Cell cycle phase analysis was performed using the FACSCalibur (Becton-Dickinson Co., San Jose, USA) and the proportion of cells within the G0/G1, S and G2/M phases was determined by analysis with ModFit LT V2.0 (Verity Software House, Topsham, USA).
Statistical analysis
The experimental results were expressed as mean±S.E.M. A one-way analysis of variance (ANOVA) was used for multiple comparison followed by Dunnett. Differences with p<0.05 were considered statistically significant.
Results
Effect of luteolin on the proliferation of VSMCs
The inhibitory effect of luteolin on proliferation of FBS-induced VSMCs was measured by cell number. The number of cells was significantly increased by 5% FBS for 24 hr. The FBS-induced cell numbers were significantly decreased by pre-treatment of luteolin for 24 hr in a concentration-dependent manner. The percentage of inhibition exerted by 5, 20 and 50 μM luteolin were 29.6, 50.8 and 83.1% respectively (Fig. 2) . (Fig. 3) . No significant difference in viability was detected between control cells and those treated with luteolin (5-50 μM) when examined by WST-1 assay (Fig. 4) .
Effect of luteolin on cell cycle progression Flow cytometric analysis (Table 1 ) demonstrated that luteolin affects cell cycle progression induced by 5% FBS. A primary culture of VSMCs was subjected to serum-deprivation for 24 hr, which resulted in approximately 87.8±075% of cells being synchronized in the G0/G1 phase. After incubation for 24 hr in the presence of FBS, the percentage of cells in S phase increased from 0.9±0.3 to 18.2±1.3%. In contrast, luteolin (5-50 μM) blocked FBS-induced cell cycle progressions in a concentration-dependent manner (Table. 1). Luteolin (5, 20 and 50 μM) reduced the percentage of FBS-stimulated cells in S phase to 14.2±1.2% (p<0.05), 9.0± 0.4% (p<0.01) and 3.5±0.6% (p<0.01), respectively (Table. 1 VSMCs were pre-cultured in serum-free medium at different concentrations (5, 20 and 50 μM) of luteolin for 24 hr, and then exposed to 5% FBS for 24 hr. Data are expressed as mean±S.E.M. from four different sets of experiments *p<0.05, **p<0.01 vs. FBS-treated VSMCs.
n=3, duplicate cultures). This finding indicates that luteolin must act during early events in the cell cycle, since it is effective against DNA synthesis. Luteolin arrested significant numbers of cells in the G1 phase of the cell cycle, suggesting that its anti-proliferative effects in VSMCs are due to cell cycle arrest. 2.7±0.9 The VSMCs were pre-cultured in the presence or absence of luteolin (5-50 μM) in serum-depleted medium for 24 hr, and then VSMCs were stimulated by 5% FBS. After 24 hr, individual nuclear DNA content was reflected by fluorescence intensity of incorporated propidium iodide. Each item is derived from a representative experiment, where data from at least 10,000 events were The aim of this study was to assess the effect of luteolin on the proliferation of serum-induced VSMCs. The antiproliferative effects of luteolin on VSMCs were examined by a direct cell counting assay. We found that luteolin is a potent inhibitor of VSMCs proliferation. The 5% FBS-induced VSMCs proliferation was significantly decreased by pre-treatment of luteolin for 24 hr in a dose-dependent manner (Fig. 2) . The inhibitory effect of luteolin on incorporation of [ 3 H]-thymidine into the cells gradually declined as the delay between the treatments of VSMCs with luteolin and FBS (Fig. 3) . In addition, the antiproliferative effect of luteolin on VSMCs was not due to cellular cytotoxicity, which were demonstrated by WST-1 assay (Fig. 4) .
Recent studies [3] have emphasized the role of G-S events in the regulation of cell proliferation through complex stimulant and inhibitory signals driven by cyclin-dependent kinases and their inhibitors, respectively. To further investigate the pattern of the antiproliferative effect of luteolin, flow cytometry analysis was performed. As revealed by flow cytometry assay, the antiproliferative effect of luteolin was associated with an accumulation of cells in G0/G1 phase of the cycle (Table 1) . Since the observed accumulation in G0/G1 reflected a specific effect of luteolin on cell cycle progression rather than a decrease of cell number due to apoptosis.
Therefore, these results suggest that anti-proliferating agent could be an useful preventive or therapeutic agent for cardiovascular diseases including atherosclerosis, and luteolin can be one of these candidate agents.
